Boehringer Ingelheim GMBH Boehringer Ingelheim has announced Phase III plans in non-small cell lung cancer for olmutinib, the third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI) it licensed from Hanmi Pharmaceutical Co. Ltd. last July.
Following the product's recent success in its originator's home market, South Korea, BI says it will comprehensively investigate olmutinib as...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)